A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
February 12, 2026 updated by: William Carson, Ohio State University Comprehensive Cancer Center
Analysis of the Tumor Microenvironment and Immune Response in Malignant Melanoma
This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals.
The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors behave.
Storing blood and tumor samples for future research may lead to new discoveries that may ultimately help with diagnosing or treating this disease.
Study Overview
Detailed Description
PRIMARY OBJECTIVE:
I. Facilitate studies aimed at investigating new prognostic markers and potentially therapeutic therapies in malignant melanoma.
OUTLINE:
Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: The Ohio State University Comprehensive Cancer Center
- Phone Number: 800-293-5066
- Email: OSUCCCClinicaltrials@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Comprehensive Cancer Center
-
Contact:
- William E. Carson, MD
- Phone Number: 614-293-6306
-
Principal Investigator:
- William E. Carson, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Patients who are being evaluated or treated for malignant melanoma by members of the departments of Surgical Oncology, Medical Oncology, and Radiation Oncology and normal controls
Description
Inclusion Criteria:
- Patient with malignant melanoma or personal history of melanoma
- Normal donors
- Informed consent can be obtained
- Patients with any stage of malignant melanoma
Exclusion Criteria:
- Incarcerated individuals will be excluded from this protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Ancillary-correlative (biospecimen collection)
Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year).
Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures.
Healthy individuals undergo collection of blood samples up to 4 times over 1 year.
|
Undergo collection of blood and tissue samples
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
New prognostic markers in malignant melanoma
Time Frame: Up to 3 months
|
Facilitate studies aimed at investigating new prognostic markers and potentially therapeutic therapies in malignant melanoma. .
Draws conducted at baseline prior to immune therapy, four weeks after draw 1 and prior to the third cycle.
|
Up to 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: William E Carson, MD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2013
Primary Completion (Estimated)
October 31, 2027
Study Completion (Estimated)
October 31, 2027
Study Registration Dates
First Submitted
September 13, 2020
First Submitted That Met QC Criteria
September 25, 2020
First Posted (Actual)
September 28, 2020
Study Record Updates
Last Update Posted (Actual)
February 17, 2026
Last Update Submitted That Met QC Criteria
February 12, 2026
Last Verified
February 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-13114
- NCI-2020-06536 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.